{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:54:25Z","timestamp":1787997265451,"version":"build-2784847793"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1124\/jpet.117.243139","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T01:00:18Z","timestamp":1504227618000},"page":"156-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Factors Contributing to the Antiviral Effectiveness of Tenofovir"],"prefix":"10.1016","volume":"363","author":[{"given":"Rachel A.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-5721","authenticated-orcid":false,"given":"Monica A.","family":"Valentovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.243139_bib1","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1124\/jpet.117.243139_bib2","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.117.243139_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/INF.0000000000000633","article-title":"Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing","volume":"34","author":"Aurpibul","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1124\/jpet.117.243139_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.2042-7158.1985.tb05051.x","article-title":"The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice","volume":"37","author":"Azmin","year":"1985","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.117.243139_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0b013e32835a9a2d","article-title":"Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults","volume":"27","author":"Baheti","year":"2013","journal-title":"AIDS"},{"key":"10.1124\/jpet.117.243139_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","article-title":"Grapefruit juice-drug interactions","volume":"46","author":"Bailey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib9","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.45.10.2733-2739.2001","article-title":"Phase i\/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults","volume":"45","author":"Barditch-Crovo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/hiv.12252","article-title":"Pharmacokinetics of tenofovir during pregnancy and postpartum","volume":"16","author":"Best","year":"2015","journal-title":"HIV Med"},{"key":"10.1124\/jpet.117.243139_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270007300951","article-title":"Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers","volume":"47","author":"Blum","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e3182302ea8","article-title":"Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients","volume":"58","author":"Bouazza","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jcph.461","article-title":"Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women","volume":"55","author":"Burns","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/jpet.117.243139_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jps.21020","article-title":"pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute","volume":"97","author":"Choi","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.117.243139_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","article-title":"Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors","volume":"12","author":"Cihlar","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.117.243139_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/jpet.117.243139_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"10.1124\/jpet.117.243139_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/135965350601100108","article-title":"Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy","volume":"11","author":"C\u00f4t\u00e9","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.117.243139_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1128\/AAC.42.3.687","article-title":"Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs","volume":"42","author":"Cundy","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib21","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","article-title":"Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults","volume":"42","author":"Deeks","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib22","first-page":"179","article-title":"Proximal tubular renal dysfunction or damage in HIV-infected patients","volume":"14","author":"Del Palacio","year":"2012","journal-title":"AIDS Rev"},{"key":"10.1124\/jpet.117.243139_bib23","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1128\/AAC.47.6.1929-1935.2003","article-title":"Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects","volume":"47","author":"DiCenzo","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/mp900036s","article-title":"Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys","volume":"6","author":"Durand-Gasselin","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.117.243139_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3851\/IMP2761","article-title":"Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration","volume":"19","author":"Ezinga","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.117.243139_bib26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/ndt\/gft010","article-title":"The clinical and histological response of HIV-associated kidney disease to antiretroviral therapy in South Africans","volume":"28","author":"Fabian","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.117.243139_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV cohort study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.117.243139_bib28","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","volume":"3","author":"Gallant","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1124\/jpet.117.243139_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","article-title":"Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV","volume":"55","author":"German","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib93","series-title":"Full Prescribing Information, Viread","year":"2001"},{"key":"10.1124\/jpet.117.243139_bib30","series-title":"Full Prescribing Information, Truvada","year":"2004"},{"key":"10.1124\/jpet.117.243139_bib31","series-title":"Full Prescribing Information, Atripla","author":"Gilead Sciences","year":"2006"},{"key":"10.1124\/jpet.117.243139_bib32","series-title":"Full Prescribing Information, Descovy","year":"2015"},{"key":"10.1124\/jpet.117.243139_bib33","series-title":"Full Prescribing Information, Genvoya","author":"Gilead Sciences","year":"2015"},{"key":"10.1124\/jpet.117.243139_bib34","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.117.243139_bib35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.117.243139_bib36","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1128\/AAC.01096-13","article-title":"Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?","volume":"57","author":"Havens","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.qai.0000167155.44980.e8","article-title":"Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens","volume":"39","author":"Hawkins","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.48.1.124-129.2004","article-title":"Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children","volume":"48","author":"Hazra","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib39","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments","volume":"8","author":"Hendrix","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/jpet.117.243139_bib40","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.117.243139_bib41","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1128\/AAC.01377-10","article-title":"Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)","volume":"55","author":"Hirt","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.bjp.0706008","article-title":"Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux","volume":"143","author":"Honda","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/QAD.0b013e328336095d","article-title":"Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045","volume":"24","author":"Jacobson","year":"2010","journal-title":"AIDS"},{"key":"10.1124\/jpet.117.243139_bib44","doi-asserted-by":"crossref","first-page":"959741","DOI":"10.1155\/2014\/959741","article-title":"Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement","volume":"2014","author":"Kamboj","year":"2014","journal-title":"Sci World J"},{"key":"10.1124\/jpet.117.243139_bib45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.117.243139_bib46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1592\/phco.29.8.924","article-title":"Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives","volume":"29","author":"Kearney","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1124\/jpet.117.243139_bib47","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.01334-10","article-title":"Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients","volume":"55","author":"King","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules","volume":"89","author":"Kohler","year":"2009","journal-title":"Lab Invest"},{"key":"10.1124\/jpet.117.243139_bib49","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1046\/j.1523-1755.1999.00769.x","article-title":"Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study","volume":"56","author":"Laurinavicius","year":"1999","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.117.243139_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/QAI.0b013e3181a666eb","article-title":"Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats","volume":"51","author":"Lebrecht","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib51","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib52","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.117.243139_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e3181427835","article-title":"Bioequivalence of efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen","volume":"46","author":"Mathias","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib55","first-page":"100","article-title":"Bioequivalence of the emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate single tablet regimen","volume":"4","author":"Mathias","year":"2012","journal-title":"J Bioequiv Avilab"},{"key":"10.1124\/jpet.117.243139_bib56","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1081\/NCN-100002483","article-title":"Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples","volume":"20","author":"Miller","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1124\/jpet.117.243139_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/jpet.117.243139_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","article-title":"Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life","volume":"65","author":"Mirochnick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/jpet.117.243139_bib60","doi-asserted-by":"crossref","first-page":"F1640","DOI":"10.1152\/ajprenal.00525.2011","article-title":"Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein","volume":"302","author":"Nomura","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.117.243139_bib61","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ajcn\/73.4.821","article-title":"Bone mineral content in girls perinatally infected with HIV","volume":"73","author":"O\u2019Brien","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/jpet.117.243139_bib62","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1023\/A:1018941328702","article-title":"Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor","volume":"16","author":"Polli","year":"1999","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.117.243139_bib63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAI.0b013e31826ea89b","article-title":"Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy","volume":"61","author":"Puthanakit","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","article-title":"Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients","volume":"37","author":"Quesada","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1124\/jpet.117.243139_bib66","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1556\/AChrom.27.2015.4.2","article-title":"A simple liquid chromatographic method for the determination of tenofovir in rat plasma and its application to pharmacokinetic studies","volume":"27","author":"Ravi","year":"2015","journal-title":"Acta Chromatogr"},{"key":"10.1124\/jpet.117.243139_bib67","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib68","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/ndt\/gfs114","article-title":"HIV-associated nephropathy: a diagnosis in evolution","volume":"27","author":"Ray","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.117.243139_bib69","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/498348","article-title":"Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus","volume":"42","author":"Saag","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1124\/jpet.117.243139_bib71","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/jpet.117.243139_bib72","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1016\/j.ijid.2012.07.019","article-title":"Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents","volume":"16","author":"Schtscherbyna","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1124\/jpet.117.243139_bib73","first-page":"436","article-title":"Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy","volume":"18","author":"Schwartz","year":"1998","journal-title":"Semin Nephrol"},{"key":"10.1124\/jpet.117.243139_bib74","first-page":"1","article-title":"Oral pharmacokinetic interaction of ester rich fruit juices and pharmaceutical excipients with tenofovir disoproxil fumarate in male Wistar rats","volume":"12","author":"Shailender","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.117.243139_bib75","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1023\/A:1012108719462","article-title":"Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs","volume":"14","author":"Shaw","year":"1997","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.117.243139_bib76","doi-asserted-by":"crossref","first-page":"e100863","DOI":"10.1371\/journal.pone.0100863","article-title":"Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.117.243139_bib77","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin Ther"},{"key":"10.1124\/jpet.117.243139_bib78","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/jcph.283","article-title":"Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study","volume":"54","author":"Shiomi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib79","first-page":"29","article-title":"Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations","volume":"9","author":"Spinks","year":"2017","journal-title":"Clin Pharmacol"},{"key":"10.1124\/jpet.117.243139_bib80","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial","volume":"139","author":"Squires","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.117.243139_bib81","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00671-07","article-title":"Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro","volume":"51","author":"Tong","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.117.243139_bib82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00002030-200103090-00007","article-title":"Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier","volume":"15","author":"van der Sandt","year":"2001","journal-title":"AIDS"},{"key":"10.1124\/jpet.117.243139_bib83","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1023\/A:1018931631912","article-title":"Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study","volume":"16","author":"Van Gelder","year":"1999","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.117.243139_bib84","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.30.8.924","article-title":"Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures","volume":"30","author":"van Gelder","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.117.243139_bib85","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"Verhelst","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.117.243139_bib86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00042560-199811010-00001","article-title":"Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells","volume":"19","author":"Washington","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1124\/jpet.117.243139_bib87","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1097\/QAD.0b013e3283060ea4","article-title":"A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle","volume":"22","author":"Wira","year":"2008","journal-title":"AIDS"},{"key":"10.1124\/jpet.117.243139_bib88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/jpet.117.243139_bib89","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med"},{"key":"10.1124\/jpet.117.243139_bib90","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semnephrol.2008.08.005","article-title":"HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy","volume":"28","author":"Wyatt","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1124\/jpet.117.243139_bib91","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ki.2008.604","article-title":"The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy","volume":"75","author":"Wyatt","year":"2009","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.117.243139_bib92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1023\/A:1011044804823","article-title":"Degradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solution","volume":"18","author":"Yuan","year":"2001","journal-title":"Pharm Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.243139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:08:23Z","timestamp":1739995703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524271469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0022356524271469"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.243139","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Contributing to the Antiviral Effectiveness of Tenofovir","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.243139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}